NO922953L - Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter - Google Patents

Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter

Info

Publication number
NO922953L
NO922953L NO92922953A NO922953A NO922953L NO 922953 L NO922953 L NO 922953L NO 92922953 A NO92922953 A NO 92922953A NO 922953 A NO922953 A NO 922953A NO 922953 L NO922953 L NO 922953L
Authority
NO
Norway
Prior art keywords
blood factors
vaccinia virus
expression
procedure
virus recombinants
Prior art date
Application number
NO92922953A
Other languages
English (en)
Other versions
NO922953D0 (no
Inventor
Falko-Guenter Falkner
Ross T A Macgillivray
Walter Bodemer
Friedrich Scheiflinger
Johann Eibl
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO922953D0 publication Critical patent/NO922953D0/no
Publication of NO922953L publication Critical patent/NO922953L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Auxiliary Devices For Machine Tools (AREA)
  • Gear Processing (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Rekombinant fremstilte blod- faktorer samt en fremgangsmåte for fremstilling derav, hvor blodfaktorene har et forhold mellom biologisk aktiv form og antigenform på minst 50 %, fortrinnsvis i området 60-90 %. Re- kombinante vacciniavirus anvendt ± den ovenfor nevnte fremgangsmåte, er også beskrevet. Fremgangsmåten gir et forbedret ekspresjonssystem med høy posttranslasjonell kapasitet og stabile ekspresjonsforhold.
NO92922953A 1990-01-26 1992-07-24 Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter NO922953L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90101623 1990-01-26
PCT/EP1991/000139 WO1991011519A1 (en) 1990-01-26 1991-01-24 Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process

Publications (2)

Publication Number Publication Date
NO922953D0 NO922953D0 (no) 1992-07-24
NO922953L true NO922953L (no) 1992-09-04

Family

ID=8203546

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922953A NO922953L (no) 1990-01-26 1992-07-24 Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter

Country Status (12)

Country Link
EP (1) EP0512011B1 (no)
JP (1) JP2549224B2 (no)
AT (1) ATE103982T1 (no)
CA (1) CA2073859A1 (no)
CS (1) CS17291A2 (no)
DE (2) DE69101634T4 (no)
DK (1) DK0512011T3 (no)
ES (1) ES2052368T3 (no)
FI (1) FI923347A7 (no)
HU (1) HUT63459A (no)
NO (1) NO922953L (no)
WO (1) WO1991011519A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5527692A (en) * 1991-12-31 1996-06-18 Zymogenetics, Inc. Methods for producing thrombin
AU683834B2 (en) * 1991-12-31 1997-11-27 Zymogenetics Inc. Methods for producing thrombin
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
EP1136553A1 (en) * 2000-03-22 2001-09-26 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7700733B2 (en) 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
DK2085470T3 (da) 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
DK1644504T3 (da) 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
JPH01502080A (ja) * 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants

Also Published As

Publication number Publication date
EP0512011A1 (en) 1992-11-11
FI923347L (fi) 1992-07-23
DK0512011T3 (da) 1994-05-09
DE69101634T2 (de) 1994-08-18
ES2052368T3 (es) 1994-07-01
HUT63459A (en) 1993-08-30
WO1991011519A1 (en) 1991-08-08
DE69101634T4 (de) 1994-12-01
DE69101634D1 (de) 1994-05-11
HU9202435D0 (en) 1992-10-28
JP2549224B2 (ja) 1996-10-30
CS17291A2 (en) 1991-09-15
NO922953D0 (no) 1992-07-24
FI923347A0 (fi) 1992-07-23
ATE103982T1 (de) 1994-04-15
JPH05507401A (ja) 1993-10-28
CA2073859A1 (en) 1991-07-27
EP0512011B1 (en) 1994-04-06
FI923347A7 (fi) 1992-07-23

Similar Documents

Publication Publication Date Title
ATE103982T1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
NO920051D0 (no) Farmasoeytisk sammensetning for slanking
DE3768546D1 (de) Mittel zur verabreichung von hyaluronsaeure an saeuger.
LU90911I2 (fr) Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
FI930694A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten nonapeptidi- ja dekapeptidianalogien valmistamiseksi, jotka ovat LHRH:n antagonisteja
ES2136599T3 (es) Tratamiento de las heridas utilizando peptidos biologicamente activos.
SE8603582D0 (sv) Komposition innehallande l-dopa
BG49827A3 (bg) Метод за получаване на пречистен биологично активен рекомбинантен човешки колоний стимулиращ фактор
EA199900751A1 (ru) Фармацевтическая композиция, содержащая лиофилизированные липосомы, включающие инкапсулированный активный ингредиент, практически нерастворимый в воде, и способ получения композиции
SE9201966D0 (sv) Interleukin-1beta deletion mutant
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
ATE126063T1 (de) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen.
ATE96662T1 (de) Verwendung von c-20 bis c-26-aliphatischen alkoholen zur herstellung eines arzneimittels zur behandlung viraler infektionen.
KR910005886A (ko) 안정화 백혈구 인터페론
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2'-desoxi -2' fluor -b- d- arabinofuranosil) -5-etiluracilo.
NO301805B1 (no) Fremgangsmåte for fremstilling av et stabilt, galenisk, vandig preparat av erytropoietin
FI880027A0 (fi) Antibakteriellt lyofiliserat preparat.
ATE48531T1 (de) Verfahren zum sterilisieren von rekombinantem mikroorganismus.
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов
FR2569721B1 (fr) Souches mutantes de listeria monocytogenes, leur procede d'obtention et vaccins vivants attenues en contenant
BG28243A3 (en) Incecticide means
FR2563219B1 (fr) Derives d'acide n-(phenylmethylthio-3 oxo-1 propyl)- aminoacetique, leur preparation et leur application en therapeutique
HU215435B (hu) Eljárás sejtkultúrák tenyésztésére alkalmas biológiai hordozó és bőrszövet-helyettesítő előállítására